Tuesday, March 23, 2021 (9:45 a.m. – 6:10 p.m. Eastern Time)

Tuesday, March 23, 2021 (9:45	
9:45 a.m. – 10:00 a.m.	Admittance to Workshop via Zoom/General Announcements
10:00 a.m. – 10:05 a.m.	 Welcome and Opening of March 2021 EDRN Scientific Workshop Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute Arul Chinnaiyan, MD, PhD, University of Michigan Sudhir Srivastava, PhD, MPH, National Cancer Institute
10:05 a.m. – 10:15 a.m.	Opening Remarks Ned Sharpless, MD, Director, National Cancer Institute
10:15 a.m. – 10:40 a.m.	Life-Time Experience with Cancer Diagnostics Robert Bast, MD, The University of Texas MD Anderson Cancer Center
10:40 a.m. – 10:45 a.m.	Q&A
10:45 a.m. – 1:15 p.m.	Session 1: Integrated Approaches to Biomarker Research
10:45 a.m. – 10:50 a.m.	 Introduction to the Session Moderators: Denise Aberle, MD, University of California, Los Angeles Hui Zhang, PhD, Johns Hopkins University School of Medicine
10:50 a.m. – 11:10 a.m.	<u>Precision Medicine of Lung Cancer: Metabolome and Microbiome</u> Curt Harris, MD, National Cancer Institute
11:10 a.m. – 11:15 a.m.	Q&A
11:15 a.m. – 11:35 a.m.	TBD Arul Chinnaiyan, MD, PhD, University of Michigan
11:35 a.m. – 11:40 a.m.	Q&A
11:40 a.m. – 11:50 a.m.	Break
11:50 a.m. – 12:10 p.m.	TBD James Herman, MD, University of Pittsburgh School of Medicine
12:10 p.m. – 12:15 p.m.	Q&A
12:15 p.m. – 12:35 p.m.	<u>The Immunogenicity of Post-Translational Protein Modifications</u> Karen Anderson, MD, PhD, Arizona State University/The Biodesign Institute
12:35 p.m. – 12:40 p.m.	Q&A
12:40 p.m. – 1:10 p.m.	TBD Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center
1:10 p.m. – 1:15 p.m.	Q&A
1:15 p.m. – 1:35 p.m.	Break
1:35 p.m. – 3:45 p.m.	Session 2: Integrated Approaches to Biomarker Research II
1:35 p.m. – 1:40 p.m.	Introduction to the Session Moderators: Surinder Batra, PhD, University of Nebraska Medical Center

o Zhen Zhang, PhD, Johns Hopkins University

Tuesday, March 23, 2021 (Continued)

1:40 p.m. – 2:00 p.m.	<u>Decoding the Cancer Mucinome</u> Carolyn Bertozzi, PhD, Stanford School of Humanities and Sciences
2:00 p.m. – 2:05 p.m.	Q&A
2:05 p.m. – 2:25 p.m.	TBD Matthew Schabath, PhD, H. Lee Moffit Cancer Center and Research Institute
2:25 p.m. – 2:30 p.m.	Q&A
2:30 p.m. – 2:50 p.m.	Multi-Disciplinary Strategies for Cancer Early Detection Victoria Seewaldt, MD, City of Hope
2:50 p.m. – 2:55 p.m.	Q&A
2:55 p.m. – 3:15 p.m.	TBD Anirban Maitra, MBBS, The University of Texas MD Anderson Cancer Center
3:15 p.m. – 3:20 p.m.	Q&A
3:20 p.m. – 3:40 p.m.	A Unique Approach Combining Avatar Mice and Mass Spectrometry to Identify Blood Biomarkers for Early Detection of Breast Cancer Amanda Paulovich, MD, PhD, Fred Hutchinson Cancer Research Center
3:40 p.m. – 3:45 p.m.	Q&A
3:45 p.m. – 4:00 p.m.	Break
4:00 p.m. – 6:10 p.m.	Session 3: Research Excellence through Alliance of Consortia
4:00 p.m. – 4:05 p.m.	Introduction to the Session Moderator: Barbara Kenner, PhD, Kenner Family Research Fund
4:05 p.m. – 4:25 p.m.	Pancreatic Cancer Detection Consortium
	Michael Goggins, MD, Johns Hopkins University School of Medicine
4:25 p.m. – 4:30 p.m.	Michael Goggins, MD, Johns Hopkins University School of Medicine Q&A
4:25 p.m. – 4:30 p.m. 4:30 p.m. – 4:50 p.m.	
	Q&A Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
4:30 p.m. – 4:50 p.m.	Q&A Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Stephen Pandol, MD, Cedars-Sinai Medical Center
4:30 p.m. – 4:50 p.m. 4:50 p.m. – 4:55 p.m.	Q&A Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Stephen Pandol, MD, Cedars-Sinai Medical Center Q&A Translational Liver Consortium
4:30 p.m. – 4:50 p.m. 4:50 p.m. – 4:55 p.m. 4:55 p.m. – 5:15 p.m.	Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Stephen Pandol, MD, Cedars-Sinai Medical Center Q&A Translational Liver Consortium Hashem El-Serag, MD, MPH, Baylor College of Medicine
4:30 p.m. – 4:50 p.m. 4:50 p.m. – 4:55 p.m. 4:55 p.m. – 5:15 p.m. 5:15 p.m. – 5:20 p.m.	Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Stephen Pandol, MD, Cedars-Sinai Medical Center Q&A Translational Liver Consortium Hashem El-Serag, MD, MPH, Baylor College of Medicine Q&A Exosomes - Rigor and Reproducibility
4:30 p.m. – 4:50 p.m. 4:50 p.m. – 4:55 p.m. 4:55 p.m. – 5:15 p.m. 5:15 p.m. – 5:20 p.m. 5:20 p.m. – 5:40 p.m.	Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Stephen Pandol, MD, Cedars-Sinai Medical Center Q&A Translational Liver Consortium Hashem El-Serag, MD, MPH, Baylor College of Medicine Q&A Exosomes - Rigor and Reproducibility David Lyden, MD, PhD, Weill Cornell Medicine
4:30 p.m. – 4:50 p.m. 4:50 p.m. – 4:55 p.m. 4:55 p.m. – 5:15 p.m. 5:15 p.m. – 5:20 p.m. 5:20 p.m. – 5:40 p.m. 5:40 p.m. – 5:45 p.m.	Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Stephen Pandol, MD, Cedars-Sinai Medical Center Q&A Translational Liver Consortium Hashem El-Serag, MD, MPH, Baylor College of Medicine Q&A Exosomes - Rigor and Reproducibility David Lyden, MD, PhD, Weill Cornell Medicine Q&A Pre-Cancer Atlas

Wednesday, March 24, 2021 (10:00 a.m. - 5:45 p.m. Eastern Time)

March 23-25, 2021

10:00 a.m. – 10:05 a.m.	 Welcome Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute Arul Chinnaiyan, MD, PhD, University of Michigan Sudhir Srivastava, PhD, MPH, National Cancer Institute
10:05 a.m. – 10:30 a.m.	Cancer Biomarkers and Disparity in Underserved Populations Olufunmilayo Olopade, MD, FACP, University of Chicago Medicine
10:30 a.m. – 1:15 p.m.	Session 4: Academic-Industry Partnership Forum Invited members will discuss the opportunity and future research trends in cancer diagnostics, market forecast and high priority.
10:30 a.m. – 10:35 a.m.	Introduction to the Session Moderator: Ernest Hawk, MD, MPH, The University of Texas MD Anderson Cancer Center
10:35 a.m. – 10:50 a.m.	TBD Josh Ofman, MD, MSHS, GRAIL
10:50 a.m. – 11:05 a.m.	TBD Peter Keeling, Diaceutics
11:05 a.m. – 11:20 a.m.	TBD Kathryn Lang, MBBS, Guardant Health
11:20 a.m. – 11:35 a.m.	Break
11:35 a.m. – 11:50 a.m.	TBD Isaac Kinde, MD, PhD, Thrive Detect
11:50 a.m. – 12:05 p.m.	TBD Graham Lidgard, PhD, Exact Sciences
12:05 p.m. – 1:15 p.m.	Panel Discussion Panelists: Eric Fung MD, PhD, GRAIL Daniel Chan PhD, Johns Hopkins University Johan Skog, Ph.D., Exosome Diagnostics Reena Philip, Ph.D., Food and Drug Administration
1:15 p.m. – 1:30 p.m.	Break
1:30 p.m. – 3:30 p.m.	Session 5: Public Health Consideration of Biomarker Research Moderators: Philip Castle, PhD, MPH, National Cancer Institute tentative Ruth Etzioni, PhD, Fred Hutchinson Cancer Research Center
	Speakers will summarize the highlights of the topics that were discussed by the EDRN Steering Committee in October 2020
1:30 p.m. – 1:50 p.m.	 What Target Sensitivity and Specificity Might Confer Clinical Utility? Steve Skates, PhD, Massachusetts General Hospital/Harvard Robert Schoen, MD, University of Pittsburgh Cancer Institute
1:50 p.m. – 2:00 p.m.	Q&A

Wednesday, March 24, 2021 (Continued)

Session 5: Public Health Cons	ideration of Biomarker Research (Continued)
2:00 p.m. – 2:20 p.m.	Modeling, Biomarkers, and Implementation Science
	 Ziding Feng, PhD, Fred Hutchinson Cancer Research Center
	 Ruth Etzioni, PhD, Fred Hutchinson Cancer Research Center
2:20 p.m. – 2:30 p.m.	Q&A
2:30 p.m. – 3:05 p.m.	Health Disparity and Biomarker Research
	 Christopher Li, MD, PhD, Fred Hutchinson Cancer Research Center
	Martin Sanda, MD, Emory University
	 Pierre Massion, MD, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical
	Center O Guest Speaker: Melissa Davis, PhD, Weill Cornell College of Medicine
3:05 p.m. – 3:15 p.m.	Q&A
3:15 p.m. – 3:35 p.m.	Study Designs for Clinical Utility Trials
3.13 p.m. – 3.33 p.m.	 Yingye Zheng, PhD, Fred Hutchinson Cancer Research Center
	Steve Skates, PhD, Massachusetts General Hospital/Harvard
3:35 p.m. – 3:45 p.m.	Q&A
3:45 p.m. – 4:00 p.m.	Break
4:00 p.m. – 5:45 p.m.	Session 6: EDRN Early Stage Investigators Presentations
4.00 p.m. – 3.43 p.m.	Moderators:
	Karin Rodland, PhD, Pacific Northwest National Laboratory
	 Louise Showe, PhD, The Wistar Institute
4:00 p.m. – 4:12 p.m.	Development of Combinatorial Biomarker Panel for Pancreatic Cancer Diagnosis
	Sukhwinder Kaur, PhD, University of Nebraska Medical Center
4:12 p.m. – 4:15 p.m.	Q&A
4:15 p.m. – 4:27p.m.	Building a Radiogenomic Portrait of Pancreatic Intraductal Papillary Mucinous Neoplasm
	Jennifer Permuth, PhD, MS, H. Lee Moffitt Cancer Center and Research Institute
4:27 p.m. – 4:30 p.m.	Q&A
4:30 p.m. – 4:42 p.m.	Digital Microfluidic Methylation Assays for the Detection of Early-Stage Ovarian Cancer
	Thomas Pisanic, PhD, Johns Hopkins University
4:42 p.m. – 4:45 p.m.	Q&A
4:45 p.m. – 4:57 p.m.	<u>Prostate</u>
	Indu Kohaar, PhD, Center for Prostate Disease Research
4:57 p.m. – 5:00 p.m.	Q&A
5:00 p.m. – 5:12 p.m.	<u>Prostate</u> Jeff Tosoian, MD, MPH, University of Michigan
5:12 p.m. – 5:15 p.m.	Q&A
5:15 p.m. – 5:27 p.m.	<u>GI</u>
	John Kisiel, MD, Mayo Clinic College of Medicine
5:27 p.m. – 5:30 p.m.	Q&A

Wednesday, March 24, 2021 (Continued)

|--|

5:30 p.m. – 5:42 p.m. Advancing MS-Based Single-Cell Proteomics

Tao Liu, PhD, Pacific Northwest National Laboratory

5:42 p.m. – 5:45 p.m. Q&A

5:45 p.m. Adjourn for the Day

Thursday, March 25, 2021 (10:00 a.m. - 7:00 p.m. Eastern Time)

10:00 a.m. – 10:05 a.m.	 Welcome Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute Arul Chinnaiyan, MD, PhD, University of Michigan
10:05 a.m. – 10:30 a.m.	 Sudhir Srivastava, PhD, MPH, National Cancer Institute Clinical Perspectives on Biomarker Research Bruce Johnson, MD, Dana-Farber Cancer Institute
10:30 a.m. – 11:50 a.m.	 Session 7: Regulatory, Reimbursement and Entrepreneurship Biomarker Research Moderators: Sudhir Srivastava, PhD, MPH, National Cancer Institute Robert Schoen, MD, University of Pittsburgh Cancer Institute

10:30 a.m. – 10:45 a.m. FDA Collaborative on Next Gen Sequencing and its Relevance to Liquid Biopsy for Early

Detection

James Willey, MD, University of Toledo

10:45 a.m. – 10:50 a.m. Q&A

10:50 a.m. – 11:05 a.m. Food and Drug Administration Perspective

Wendy Rubinstein, MD, PhD, Director of Personalized Medicine

11:05 a.m. – 11:10 a.m. Q&A

11:10 a.m. – 11:25 a.m. Center for Medicare and Medicaid Services Perspective

Melissa Evans, PhD, Director of the Division of Policy and Evidence Review, CMS

o Carl Li, MD, MPH, Medical Officer, CMS

11:25 a.m. – 11:30 a.m. Q&A

11:30 a.m. – 11:45 a.m. SBIR Developmental Center: Research and Development Opportunities

Michael Weingarten, MA, Director, Small Business Innovation Research, National Cancer

Institute

11:45 a.m. – 11:50 a.m. Q&A

11:50 a.m. – 12:10 p.m. Break

12:10 p.m. – 3:10 p.m. Poster/Interactive Session & Lightning Talks from Posters (5 minute Presentations)

NCI Program Directors:

o Lynn Sorbara, PhD, National Cancer Institute

Natalie Abrams, PhD, National Cancer Institute

12:10 p.m. – 1:10 p.m. Poster Highlights Session

Thursday, March 25, 2021 (Continued)

Poster/Interactive Session & Lightning Talks from Posters (5 minute Presentations)

1:10 p.m. – 3:10 p.m. Poster Viewing Session

3:10 p.m. – 5:00 p.m. Break

5:00 p.m. – 7:00 p.m. Poster/Interactive Session & Lightning Talks from Japan Investigators (AMED P-CREATE)

5:00 p.m. – 6:00 p.m. Poster Highlights Session
6:00 p.m. – 7:00 p.m. Poster Viewing Session

7:00 p.m. Adjourn Scientific Workshop